Polyclonal Regulatory T Cell Manufacturing Under cGMP: A Decade of Experience

We report on manufacturing outcomes for 41 autologous polyclonal regulatory T cell (PolyTreg) products for 7 different Phase 1 clinical trials over a 10-year period (2011-2020). Data on patient characteristics, manufacturing parameters, and manufacturing outcomes were collected from manufacturing ba...

Description complète

Enregistré dans:

Détails bibliographiques
Auteurs principaux:	Joanna Balcerek, Brian R. Shy, Amy L. Putnam, Lisa M. Masiello, Angela Lares, Florinna Dekovic, Luis Acevedo, Michael R. Lee, Vinh Nguyen, Weihong Liu, Sreenivasan Paruthiyil, Jingying Xu, Ashley S. Leinbach, Jeffrey A. Bluestone, Qizhi Tang, Jonathan H. Esensten
Format:	article
Langue:	EN
Publié:	Frontiers Media S.A. 2021
Sujets:	regulatory T cell manufacturing cGMP ex vivo expansion cellular therapy regulatory T cells Immunologic diseases. Allergy RC581-607
Accès en ligne:	https://doaj.org/article/4fbc3387d354494ba9daa3d9eab90fba
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!

Soyez le premier à ajouter un commentaire!

Polyclonal Regulatory T Cell Manufacturing Under cGMP: A Decade of Experience

Documents similaires